Brief Title
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
Official Title
A Phase I Trial to Evaluate Safety and Immunogenicity of a Cytomegalovirus Peptide Vaccine Co-Injected With PF-03512676 Adjuvant in Recipients of Allogeneic Hematopoietic Stem Cell Transplant
Brief Summary
This randomized phase I trial studies the side effects of vaccine therapy in preventing
cytomegalovirus (CMV) infection in patients with hematological malignancies undergoing donor
stem cell transplant. Vaccines made from a tetanus-CMV peptide or antigen may help the body
build an effective immune response and prevent or delay the recurrence of CMV infection in
patients undergoing donor stem cell transplant for hematological malignancies.
Detailed Description
PRIMARY OBJECTIVES: I. To discover whether two administrations of 2.5 mg tetanus (Tet)-CMV
peptide co-injected with 1 mg of PF-03512676 (tetanus-CMV fusion peptide vaccine), by
subcutaneous (SC) route on days 28 and 56 post-hematopoietic cell transplantation (HCT) are
safe and well tolerated in human leukocyte antigen (HLA) A*0201 CMV-positive recipients of
allogeneic HCT.
SECONDARY OBJECTIVES:
I. To measure levels of CMV-specific T cells in vaccinated compared to unvaccinated HCT
recipients (control arm).
II. To assess whether vaccination of HCT recipients with Tet-CMV co-injected with PF03512676
reduces expression of programmed death 1 (PD-1) on CMV-specific T cells.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive Tet-CMV + PF03512675 SC on days 28 and 56 post-HCT.
ARM II: Patients undergo immune monitoring only.
After completion of study treatment, patients are followed up at days 70, 84, 100, 130, 160,
and 180.
Study Phase
Phase 1
Study Type
Interventional
Primary Outcome
Safety based on assessment of GVHD, graded according to the Keystone Consensus system and adverse events (AEs) based on National Cancer Institute (NCI) CTCAE version 4.03
Secondary Outcome
Immunogenicity evaluated by monitoring CMV-specific CD8+ T cells by multi color flow cytometric analyses
Condition
Accelerated Phase Chronic Myelogenous Leukemia
Intervention
tetanus-CMV fusion peptide vaccine
Study Arms / Comparison Groups
Arm I (vaccine therapy)
Description: Patients receive Tet-CMV + PF03512675 SC on days 28 and 56 post-HCT.
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Biological
Estimated Enrollment
36
Start Date
October 29, 2012
Completion Date
November 30, 2023
Primary Completion Date
November 30, 2023
Eligibility Criteria
Inclusion Criteria:
- HLA A*0201 subtype
- CMV seropositive
- Able and willing to sign the informed consent form (ICF)
- Willingness to be followed for the planned duration of the trial (6 months post-HCT)
- Seronegative for human immunodeficiency virus (HIV), hepatitis C virus (HCV) and
active hepatitis B virus (HBV) (surface antigen negative)
- Planned related or unrelated HCT, with 8/8 or 7/8 (A, B, C, DRB1) high resolution HLA
donor allele matching
- HCT for the treatment of hematologic cancers including, but not limited to:
- Acute lymphoblastic leukemia in first or second remission (for acute
lymphoblastic leukemia/lymphoblastic lymphoma, the disease status needs to be in
hematologic remission by bone marrow/peripheral blood; persistent lymphadenopathy
on computed tomography [CT] or CT/positron emission tomography [PET] scan without
progression is allowed)
- Chronic myelogenous leukemia in first chronic or accelerated phase, or in second
chronic phase
- Hodgkin and non-Hodgkin lymphoma
- Myelodysplastic syndrome
- Planned HCT with minimal to no-T cell depletion of graft
- Use of contraception up to 90 days post-HCT
- Negative pregnancy test for female recipient
- DISEASE STATUS: Recipients to be enrolled are patients eligible for allogeneic HCT,
who were diagnosed with hematologic cancers including:
- Acute lymphoblastic leukemia (ALL); B-precursor ALL; T cell ALL
- Acute myeloid leukemia (AML), acute promyelocytic leukemia; treatment related AML
- Chronic lymphoid leukemia; adult T cell leukemia/lymphoma, chronic lymphocytic
leukemia not otherwise specified (NOS), hairy cell leukemia; prolymphocytic leukemia
(B or T); T cell large granular (gran.) lymphocytic (lymph.) leukemia (leuk)
- Chronic myeloproliferative disease (CML); chronic eosinophilic leukemia
(CEL)/hypereosinophilic syndrome; chronic idiopathic myelofibrosis; CML - Philadelphia
chromosome; essential thrombocythemia; polycythemia vera
- Leukemia, not otherwise specified (NOS)
- Myelodysplastic syndrome, NOS; chronic myelomonocytic leukemia
- Hodgkin lymphoma, NOS; Hodgkin lymphoma nodular lymphocyte predominant (LP), NOS;
Hodgkin lymphoma - like post-transplant lymphoproliferative disorder (PTLD)
- Lymphoma, NOS
- Non-Hodgkin lymphoma (NHL); anaplastic large-cell lymphoma (ALCL), cutaneous, ALCL,
systemic; Burkitt lymphoma/leukemia; cutaneous T-cell lymphoma (CTCL)/mycosis
fungoides; CTCL/Sezary syndrome; diffuse large B-cell lymphoma; mucosa associated
lymphoid tissue (MALT)-lymphoma; extranodal natural killer (NK)/T cell lymphoma,
extranodal NK/T lymphoma nasal; follicular lymphoma; lymphoplasmacytic lymphoma mantle
cell lymphoma; mediastinal large B-cell lymphoma; nodal marginal zone B-cell lymphoma
(lymph.); NHL aggressive, NOS; NHL indolent, NOS; NHL, NOS; peripheral T cell
lymphoma, NOS; PTLD (monoclonal); PTLD (polyclonal); precursor (precur.)
B-lymphoblastic lymphoma; precur T-lymphoblastic lymphoma; primary central nervous
system (CNS) lymphoma; primary effusion lymphoma; small lymphocytic lymphoma, NOS
- Myeloma, NOS; monoclonal gammopathy of undetermined significance (MGUS); solitary
plasmacytoma
- Women of child-bearing potential and men must agree to use adequate contraception
(hormonal or barrier method of birth control or abstinence) prior to study entry and
for six months following duration of study participation; should a woman become
pregnant or suspect that she is pregnant while participating on the trial, she should
inform her treating physician immediately
- All medications, supportive care, blood products or radiation therapy taken or
administered during the trial will be documented in the subject's clinical/hospital
and case report form (CRF), using City of Hope (COH) guidelines; the subject's
clinical information will be recorded on the appropriate CRF
- Concurrent enrollment in other clinical trials using an investigational product is
prohibited
- The use of alemtuzumab for immunosuppression is not permitted in this study
- Prophylactic therapy with CMV immunoglobulin or prophylactic antiviral CMV treatment
is not allowed
- Medications that might interfere with the evaluation of the investigational product
should not be administered, from 30 days prior to participation on the trial and up to
14 days after the second vaccination (day 70 post-HCT); medications in this category
include, but are not limited to:
- Live attenuated vaccines
- Medically indicated subunit (Engerix-B for HBV; Gardasil for HPV) or killed
vaccines (e.g. influenza, pneumococcal, or allergy treatment with antigen
injections)
- Antiviral treatment for herpes simplex virus (HSV), human herpes virus 6 (HHV6),
Epstein-Barr virus (EBV) and adenovirus including the use of GVC/VAL, FOS, Cidofovir,
CMX-001 may also suppress reactivation of CMV, thus it will not be allowed in this
study; patients requiring such treatment before randomization (day 28) will be removed
from the study and replaced; reasons for removal will be reported in the patient's CRF
- All enrolled recipients who will require anti-CMV therapy before day 28 will be
replaced, treated and monitored as required by COH standard of care; GVC/VAL, FOS,
Cidofovir, CMX-001 may be used according to COH standard of care (SOC) for preemptive
management of CMV viremia; should antiviral treatment be required after day 28, the
planned 2nd vaccine injection at day 56 will not be administered (vaccine arm only)
- All subjects must have the ability to understand and the willingness to sign a written
informed consent
Exclusion Criteria:
- A poor-risk patient, as defined by any of the following:
- Chronic myelogenous leukemia in blast crisis
- Acute myeloid leukemia beyond second remission
- Multiple myeloma
- Aplastic anemia
- Planned immunosuppression with alemtuzumab or any equivalent in vivo T-cell depleting
agent
- In vitro T cell depleted graft
- Planned prophylactic therapy with CMV immunoglobulin
- Planned CMV prophylactic therapy
- Experimental anti-CMV chemotherapy in the last 6 months
- Diagnosed with autoimmune disease
- Receipt of the following substances:
- Any prior investigational CMV vaccine
- Live attenuated vaccines, medically indicated subunit or killed vaccines from 30
days prior to participation in the trial and up to 14 days after the second
vaccination (day 70 post-HCT)
- Investigational research products or allergy treatment with antigens injections
from 30 days prior to participation in the trial and up to 14 days after the
second vaccination (day 70 post-HCT)
- Pregnant and/or breast feeding if a female recipient
- Refusing to use contraception up to 90 days post-HCT
- POST-HCT STUDY-SPECIFIC EXCLUSIONS:
- On days 28 and 56 post-HCT (immunization day for the vaccine arm) all study recipients
(vaccine and observation arms) will be reviewed for eligibility and ruled ineligible
to initiate or continue in the study and receive vaccination (for the vaccine arm) if:
- Diagnosed with > grade 2 graft-versus-host disease (GVHD) before day 28 post-HCT,
and diagnosed with > grade 2 GVHD between day 28 post-HCT and administration of
the 2nd vaccine at day 56
- Received steroid therapy with prednisone > 1 mg/kg/day, less than 7 days prior to
injection
- Had relapse
- Experience graft failure (absolute neutrophil count < 500/mm^3)
- Received antiviral treatment with GVC/VAL, FOS, Cidofovir, CMX-001 at any point
during the 28 day period
- There are ongoing non-hematological post-HCT toxicities >= grade 3
non-hematological (hem) adverse events (AE's), with exception of grade 3 glucose
intolerance and grade 3 non-hem labs; cholesterol, triglyceride, and
hyperglycemia
Gender
All
Ages
18 Years - 75 Years
Accepts Healthy Volunteers
No
Contacts
Ryotaro Nakamura, ,
Location Countries
United States
Location Countries
United States
Administrative Informations
NCT ID
NCT01588015
Organization ID
12022
Secondary IDs
NCI-2012-00589
Responsible Party
Sponsor
Study Sponsor
City of Hope Medical Center
Collaborators
National Cancer Institute (NCI)
Study Sponsor
Ryotaro Nakamura, Principal Investigator, City of Hope Medical Center
Verification Date
February 2023